Their further study on 77 breast cancer cell lines reveals that BRD4 is a putative targeted option for luminal breast cancer and PIK3CA mutations probably determine the resistance to bromodomain and extra-terminal domain (BET)-inhibitors [112]. The gene discussed is BRD4; the disease is breast carcinoma.